See the DrugPatentWatch profile for fintepla

Does Fintepla Offer Patient Assistance Programs?

Understanding Fintepla: A Breakthrough Treatment for Seizures

Fintepla, also known as fenfluramine, is a medication used to treat seizures in patients with Dravet syndrome, a rare and severe form of epilepsy. Developed by Marinus Pharmaceuticals, Fintepla has shown promising results in reducing seizure frequency and improving quality of life for patients with this condition. However, one of the concerns for patients and caregivers is the cost of this medication. In this article, we will explore whether Fintepla offers patient assistance programs to help make this treatment more accessible.

The High Cost of Fintepla

Fintepla is a prescription medication that is not cheap. The average monthly cost of Fintepla can range from $3,000 to $6,000, depending on the dosage and patient's insurance coverage. This can be a significant financial burden for patients and their families, especially those who are already struggling with the emotional and physical challenges of living with epilepsy.

Patient Assistance Programs: A Lifeline for Patients

Patient assistance programs (PAPs) are designed to help patients who are struggling to afford their medications. These programs provide financial assistance, free or low-cost medications, and other support services to eligible patients. Many pharmaceutical companies, including Marinus Pharmaceuticals, offer PAPs to help make their medications more accessible.

Does Fintepla Offer a Patient Assistance Program?

According to DrugPatentWatch.com, a leading source for pharmaceutical patent information, Marinus Pharmaceuticals, the manufacturer of Fintepla, does offer a patient assistance program. The program, called the Fintepla Patient Assistance Program, provides eligible patients with free or low-cost Fintepla medication.

Eligibility Criteria for the Fintepla Patient Assistance Program

To be eligible for the Fintepla Patient Assistance Program, patients must meet certain criteria, including:

* Being a resident of the United States
* Having a valid prescription for Fintepla
* Having a household income at or below 200% of the federal poverty level
* Not being eligible for Medicaid or other government-funded programs

How to Apply for the Fintepla Patient Assistance Program

Patients who are interested in applying for the Fintepla Patient Assistance Program can do so by visiting the Marinus Pharmaceuticals website or by contacting the program directly. The application process typically involves providing proof of income, insurance information, and a valid prescription for Fintepla.

Other Resources for Patients with Epilepsy

While the Fintepla Patient Assistance Program can provide financial assistance, it's not the only resource available to patients with epilepsy. Other organizations, such as the Epilepsy Foundation and the Dravet Syndrome Foundation, offer a range of services, including education, support groups, and advocacy.

Conclusion

Fintepla is a breakthrough treatment for seizures in patients with Dravet syndrome, but its high cost can be a significant barrier for many patients. Fortunately, Marinus Pharmaceuticals offers a patient assistance program that can help make this medication more accessible. By understanding the eligibility criteria and application process, patients can take advantage of this program and receive the treatment they need to manage their seizures.

FAQs

1. What is the Fintepla Patient Assistance Program?
The Fintepla Patient Assistance Program is a program offered by Marinus Pharmaceuticals that provides eligible patients with free or low-cost Fintepla medication.

2. Who is eligible for the Fintepla Patient Assistance Program?
Patients who are residents of the United States, have a valid prescription for Fintepla, and have a household income at or below 200% of the federal poverty level are eligible for the program.

3. How do I apply for the Fintepla Patient Assistance Program?
Patients can apply for the program by visiting the Marinus Pharmaceuticals website or by contacting the program directly.

4. What other resources are available to patients with epilepsy?
Patients with epilepsy can access a range of services, including education, support groups, and advocacy, from organizations such as the Epilepsy Foundation and the Dravet Syndrome Foundation.

5. Is Fintepla a covered medication under Medicare or Medicaid?
Fintepla is not currently a covered medication under Medicare or Medicaid. However, patients who are eligible for the Fintepla Patient Assistance Program may be able to receive free or low-cost medication.

Cited Sources:

1. Marinus Pharmaceuticals. (n.d.). Fintepla Patient Assistance Program. Retrieved from <https://www.marinuspharma.com/patient-assistance-program/>

2. DrugPatentWatch.com. (n.d.). Fintepla (fenfluramine) Patent Information. Retrieved from <https://www.drugpatentwatch.com/patent/US-107-934-2020-FENFLURAMINE-FINTEPLA/>

3. Epilepsy Foundation. (n.d.). Patient Assistance Programs. Retrieved from <https://www.epilepsy.com/patient-assistance-programs>

4. Dravet Syndrome Foundation. (n.d.). Patient Assistance Programs. Retrieved from <https://www.dravetfoundation.org/patient-assistance-programs/>